Erlocip (Erlotinib 150mg Tablets)

Erlocip (Erlotinib 150mg Tablets) is an anti-cancer medication which works by blocking the epidermal growth factor receptor (EGFR). This helps to inhibit the growth of cancer cells. Indications include first line treatment of metastatic NSCLC (non-small cell lung cancer) and pancreatic cancer. Patients being treated for pancreatic cancer will also be treated with another cancer medicine (gemcitabine). The main ingredient in this drug is classified as a kinase inhibitor. Its mechanism of action is inhibiting the kinase activity of the epidermal growth factor receptor (EGFR). The EGFRs are present on the cell surface and they help the epidermal growth factor (a type of protein which is known to stimulate the growth of cells) attach itself to the cells, resulting in the activation of an enzyme known as tyrosine kinase. This enzyme helps trigger growth in the cancer cells. However, this medicine reversibly inhibits EGFR action, which disrupts the entire chemical process that causes the growth of the cancer cells, thereby preventing the multiplication of the cancer cells. Medical tests may be required by your physician to determine whether or not the cancer is likely to be responsive to treatment with this medicine.

• Model: Erlocip
• Brand: Cipla